MYCN’s ability to induce MDM2 in cone precursors contrasts with its failure to upregulate MDM2 in sympathetic ganglion cells that initiate tumorigenesis in the TH-MYCN transgenic mouse neuroblastoma model, where MYCN engaged an alternative BMI1-mediated resistance to p53 signaling (43). This evidence concerns the gene MYCN and neuroblastoma.